Programa de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Serviço de Genética Médica, HCPA, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, CEP 90035-003, Brazil.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1563-1569. doi: 10.1007/s00210-023-02423-7. Epub 2023 Feb 16.
Niemann-Pick type C1 (NP-C1) is a lysosomal storage disease (LSD) caused by mutations in NPC1 gene that lead to defective synthesis of the respective lysosomal transporter protein and cholesterol accumulation in late endosomes/lysosomes (LE/L) compartments, as well as glycosphingolipids GM2 and GM3 in the central nervous system (CNS). Clinical presentation varies according to the age of onset and includes visceral and neurological symptoms, such as hepatosplenomegaly and psychiatric disorders. Studies have been associating the pathophysiology of NP-C1 with oxidative damage to lipids and proteins, as well as evaluating the benefits of adjuvant therapy with antioxidants for this disease. In this work, we evaluated the DNA damage in fibroblasts culture from patients with NP-C1 treated with miglustat, as well as the in vitro effect of the antioxidant compounds N-acetylcysteine (NAC) and Coenzyme Q10 (CoQ10), using the alkaline comet assay. Our preliminary results demonstrate that NP-C1 patients have increased DNA damage compared to healthy individuals and that the treatments with antioxidants can mitigate it. DNA damage may be due to an increase in reactive species since it has been described that NP-C1 patients have increased peripheral markers of damage to other biomolecules. Our study suggests that NP-C1 patients could benefit from the use of adjuvant therapy with NAC and CoQ10, which should be better evaluated in a future clinical trial.
尼曼-匹克 C1 型(NP-C1)是一种溶酶体贮积病(LSD),由 NPC1 基因突变引起,导致溶酶体转运蛋白合成缺陷,胆固醇在内体/溶酶体(LE/L)腔室以及中枢神经系统(CNS)中的神经节苷脂 GM2 和 GM3 中蓄积。临床表现取决于发病年龄,包括内脏和神经症状,如肝脾肿大和精神障碍。研究将 NP-C1 的病理生理学与脂质和蛋白质的氧化损伤联系起来,并评估了抗氧化剂辅助治疗这种疾病的益处。在这项工作中,我们使用碱性彗星试验评估了用米格列醇治疗的 NP-C1 患者成纤维细胞培养物中的 DNA 损伤,以及抗氧化剂化合物 N-乙酰半胱氨酸(NAC)和辅酶 Q10(CoQ10)的体外作用。我们的初步结果表明,与健康个体相比,NP-C1 患者的 DNA 损伤增加,抗氧化剂治疗可以减轻这种损伤。DNA 损伤可能是由于活性物质增加所致,因为已经描述了 NP-C1 患者其他生物分子的外周损伤标志物增加。我们的研究表明,NP-C1 患者可能受益于使用 NAC 和 CoQ10 的辅助治疗,这应该在未来的临床试验中进行更好的评估。